A private specialty pharmaceutical company with offices all around the world has a venture fund that focuses on early stage companies.  The firm positions itself to be a strategic corporate partner to develop and support innovative technologies in the aesthetics and cosmetics space. The firm typically makes $1-$5 million investments. The firm is seeking 4-5 investments in early-stage companies, start-ups including spinout companies from academia. The firm is geographically agnostic, and is open to investments from all over the world.

The firm focuses only on aesthetics with an anti-aging focus, including skin rejuvenation, body shaping and modification. The firm is open to all therapeutics, medical devices, and healthcare IT, as long as the technology serves an unmet need/gap in the aesthetic marketplace. The firm historically invested in injectables, toxins, topicals, cosmetics, and devices. The firm typically looks at seed to early stage companies, and specifically focuses on pre-clinical to clinical stage technology with substantial data.

As a strategic corporate partner, the firm hopes to bring its own expertise and internal resources to the table. As not only an investor, but also as a strategic partner, the firm anticipates being able to offer advice, support, and consultation for the early-stage company to leverage its global comprehensive network of experts within the firm, and can offer R&D, clinical, regulatory through to commercial, sales and marketing expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private investment firm based in New York, NY has launched a health technology fund to invest in early stage companies that are developing innovations that can significantly reduce healthcare costs. The firm makes equity investments where the investment size is highly variable depending on the stage of development and particular need of each company. The firm invests in companies that are based in the US and is actively seeking new investment opportunities.

The fund focuses on early-stage healthcare IT projects that could substantially lower the cost of healthcare delivery in the United States. Examples of good candidates include projects that help consumers make more informed decisions when selecting local service providers (cost transparency); use remote monitoring technology to help patients better manage illness; or provide more meaningful tracking of health metrics for patients (health and wellness analytics).

The firm is an active and engaged investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Hong Kong makes seed and early stage investments across several sectors including the life sciences. The firm typically allocates USD 75K to 500K per company as well as possible continuation into Series A. The firm can invest globally and is actively seeking new investment opportunities.

In the life sciences, the firm is interested in DNA genetic testing. For example, technologies such as pre-natal testing and DNA testing for oncology screening. The firm is also interested in and health & wellness technology for preventive care or management of chronic illness such as diabetes. The firm will focus on startups that have already gained some traction. The firm historically invested in molecular diagnostics and DNA screening.

The firm looks to partner with exceptional entrepreneurs and generally looks to take a board seat post investment, though this is not a requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the United Kingdom seeks to invest in companies that need capital within the range of £1m to £10m with a typical investment size at £3 million per company. The firm focuses on investments in life science companies at clinical or growth stage. The firm has a syndicated fund of £100 million, and seeks to make 1-2 new investments within the next year in addition to their current portfolio of 8 active companies. The firm typically leads investments, though will co-invest depending on the opportunity. The firm focuses on UK-based private companies, though is open to companies based in Europe and the U.S.

The firm is currently looking for new opportunities in the Medical Technology and Therapeutics sectors. The firm will also consider diagnostics companies, depending on the opportunity. For therapeutics, the firm will invest in both small molecules and biologics. The firm will consider all classes of medical devices, and prefers to invest in devices with a regulatory pathway. The firm invests in clinical-stage to commercialized products, and prefers clinical-stage technology with a clear path towards revenue.

The firm focuses on private companies and prefers companies with a strong management team and significant growth potential that are able to deliver returns for investors within a 3 to 5-year timetable. The firm looks to take a board seat post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the central US is currently in the process of raising its 2nd fund, targeted at $50 million. The firm typically makes equity co-investments in seed and early stage companies ranging from $50,000 to $8 million with most investments in the $250,000 to $1.5 million range. The firm typically makes 6-8 allocations per year, and is open to opportunities throughout the United States and Canada.

The firm is looking for companies in telemedicine, healthcare IT, pathology, diagnostics, bioinformatics, medical devices, and healthcare automation. The firm does not look at pharmaceutical opportunities. The firm is interested in early stage companies from pre-prototype or pre-clinical to clinical stage that have a cost efficient and innovative product with a clear pathway to exit in approximately 3-5 years. The firm is open to consider all indications and types of devices. The firm is not interested in late stage investments into companies that already have a product on the market. The firm focuses on opportunities that focus on patient care improvements, healthcare IT or products that solve critical problems that hospitals, doctors or patients face—and for which the company can receive reimbursement.

The firm is looking for entrepreneur-based management teams with experience who are open to work with them. The firm looks to take a board seat following investment. In addition to capital, the firm is capable of providing strategic mentoring as well as incubation services both locally and remotely in areas of HR, Marketing, Accounting and Software Development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment firm with offices in the USA and Europe manages focused private equity funds for family offices and high-net worth individuals. The firm seeks to transform SMEs with local traction to global front-runners. Their typical investment size is $1 M – 20 M. They are looking to make 4 new investments in the next year, and are currently focused on OTM medical technology.

The firm is opportunistic and will consider deals across the life sciences board, but is currently focused on medical technology, industrial processes, materials, HCIT and digital health with high tech underpinnings, and food production, distribution, and transformation.

The firm desires an experienced, passionate team of entrepreneurs with international experience, capable of building a fast growing global business. They do not invest in start ups. They look to acquire 20-80% equity in SME’s with $3-5 M in revenue, or fast growing companies that will be generating revenue within a year with all regulatory barriers cleared. They require a clear, scalable path to globalization. The firm pursues a 60-day due diligence period when considering a deal.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A joint venture investment company backed by two large corporations is investing in healthcare from a $100 million fund. The firm strives to catalyze the success of digital medicine products, services and business models by investing in early-stage companies. The firm prefers to co-invest and makes equity investments of up to $5 million per deal. The firm is currently seeking opportunities in the US, EU, and Israel.

The firm is seeking entrepreneurs using digital technology to transform pharmaceutical products, sales and marketing, R&D, and enterprise operations. The firm also considers personalized medicine using -omics science. Examples may include enterprise software solutions that improves clinical care or mobile sensors for disease management in home care settings. The firm is less interested in consumer products. The firm is seeking products with some market traction or credible customers.

The firm works with strong founders who demonstrate full understanding of their market sector.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com